Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.57

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.01

EPS Last/This Y

0.29

EPS This/Next Y

0.03

Price

0.86

Target Price

3.76

Analyst Recom

1.43

Performance Q

-53.51

Relative Volume

0.26

Beta

1.3

Ticker: IFRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04IFRX0.80240.000.002430
2025-07-07IFRX0.820.000.002453
2025-07-08IFRX0.87590.000.002466
2025-07-09IFRX0.88110.000.003578
2025-07-10IFRX0.90020.000.003601
2025-07-11IFRX0.88820.000.003654
2025-07-14IFRX0.8770.000.003654
2025-07-15IFRX0.84080.000.003654
2025-07-16IFRX0.85240.000.003677
2025-07-17IFRX0.85380.000.003789
2025-07-18IFRX0.86640.000.003789
2025-07-21IFRX0.8520.000.001863
2025-07-22IFRX0.8420.000.001924
2025-07-23IFRX0.86030.000.002059
2025-07-24IFRX0.85890.000.002117
2025-07-25IFRX0.89220.000.002130
2025-07-28IFRX0.88740.000.002220
2025-07-29IFRX0.8870.000.002363
2025-07-30IFRX0.8940.000.002462
2025-07-31IFRX0.9040.000.002562
2025-08-01IFRX0.870.000.002674
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04IFRX0.8015.3- -0.63
2025-07-07IFRX0.8215.3- -0.63
2025-07-08IFRX0.8815.3- -0.63
2025-07-09IFRX0.8915.3- -0.63
2025-07-10IFRX0.9015.3- -0.63
2025-07-11IFRX0.8815.3- -0.63
2025-07-14IFRX0.8915.3- -0.63
2025-07-15IFRX0.8115.3- -0.63
2025-07-16IFRX0.8515.3- -0.63
2025-07-17IFRX0.8715.3- -0.63
2025-07-18IFRX0.8715.3- -0.63
2025-07-21IFRX0.8515.3- -0.63
2025-07-22IFRX0.8315.3- -0.63
2025-07-23IFRX0.8615.3- -0.63
2025-07-24IFRX0.8515.3- -0.63
2025-07-25IFRX0.9015.3- -0.63
2025-07-28IFRX0.8915.3- -0.63
2025-07-29IFRX0.8715.3- -0.63
2025-07-30IFRX0.8815.3- -0.63
2025-07-31IFRX0.9015.3- -0.63
2025-08-01IFRX0.8615.3- -0.63
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04IFRX0.0070.391.89
2025-07-07IFRX0.0070.391.89
2025-07-08IFRX0.0070.391.89
2025-07-09IFRX0.0070.391.89
2025-07-10IFRX0.0070.391.89
2025-07-11IFRX0.0070.391.98
2025-07-14IFRX0.0070.391.98
2025-07-15IFRX0.0070.391.98
2025-07-16IFRX0.0070.391.98
2025-07-17IFRX0.0070.391.98
2025-07-18IFRX0.0070.391.98
2025-07-21IFRX0.0070.221.98
2025-07-22IFRX0.0070.221.98
2025-07-23IFRX0.0070.221.98
2025-07-24IFRX0.0070.221.98
2025-07-25IFRX0.0070.221.57
2025-07-28IFRX0.0069.771.57
2025-07-29IFRX0.0069.771.57
2025-07-30IFRX0.0069.771.57
2025-07-31IFRX0.0069.771.57
2025-08-01IFRX0.0069.771.57
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.14

Avg. EPS Est. Current Quarter

-0.2

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

Institutional Transactions

69.77

Beta

1.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

24

Growth Score

28

Sentiment Score

71

Actual DrawDown %

88.1

Max Drawdown 5-Year %

-88.5

Target Price

3.76

P/E

Forward P/E

PEG

P/S

320.77

P/B

0.77

P/Free Cash Flow

EPS

-1.05

Average EPS Est. Cur. Y​

-0.63

EPS Next Y. (Est.)

-0.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-33446.81

Relative Volume

0.26

Return on Equity vs Sector %

-87.2

Return on Equity vs Industry %

-68.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.02

EBIT Estimation

InflaRx N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 74
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
stock quote shares IFRX – InflaRx N.V. Stock Price stock today
news today IFRX – InflaRx N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch IFRX – InflaRx N.V. yahoo finance google finance
stock history IFRX – InflaRx N.V. invest stock market
stock prices IFRX premarket after hours
ticker IFRX fair value insiders trading